We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Bristol-Myers Squibb (BMY - Free Report) closed the most recent trading day at $57.41, moving +0.83% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.86%. At the same time, the Dow lost 0.96%, and the tech-heavy Nasdaq lost 1.13%.
Heading into today, shares of the biopharmaceutical company had lost 0.75% over the past month, lagging the Medical sector's gain of 6.39% and the S&P 500's gain of 3.66% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. On that day, BMY is projected to report earnings of $0.94 per share, which would represent no growth from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $6.16 billion, up 3.11% from the prior-year quarter.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $24.93 billion. These results would represent year-over-year changes of +10.05% and +10.51%, respectively.
It is also important to note the recent changes to analyst estimates for BMY. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.26% higher. BMY is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, BMY currently has a Forward P/E ratio of 13.01. For comparison, its industry has an average Forward P/E of 15.06, which means BMY is trading at a discount to the group.
It is also worth noting that BMY currently has a PEG ratio of 1.32. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 2.1 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 33, putting it in the top 13% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Bristol-Myers Squibb (BMY - Free Report) closed the most recent trading day at $57.41, moving +0.83% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.86%. At the same time, the Dow lost 0.96%, and the tech-heavy Nasdaq lost 1.13%.
Heading into today, shares of the biopharmaceutical company had lost 0.75% over the past month, lagging the Medical sector's gain of 6.39% and the S&P 500's gain of 3.66% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. On that day, BMY is projected to report earnings of $0.94 per share, which would represent no growth from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $6.16 billion, up 3.11% from the prior-year quarter.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $24.93 billion. These results would represent year-over-year changes of +10.05% and +10.51%, respectively.
It is also important to note the recent changes to analyst estimates for BMY. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.26% higher. BMY is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, BMY currently has a Forward P/E ratio of 13.01. For comparison, its industry has an average Forward P/E of 15.06, which means BMY is trading at a discount to the group.
It is also worth noting that BMY currently has a PEG ratio of 1.32. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 2.1 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 33, putting it in the top 13% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.